FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM) (MIM)

This is an interventional diagnostic trial for Multiple Myeloma focused on measuring PET/CT, FDG, Fluorocholine (18F) FCH Read More

Inclusion Criteria:

• Patient with initial diagnosis of multiple myeloma has just been established
• Therapeutic indication and eligible for a HSC autograft (if the HSC autograft could not be performed, the patient will still be retained in the study).
• Status ECOG 0, 1 or 2
• Age ≥ 18 and < 75 ans years
• Effective contraception for women
• Informed consent signed
• Patient able to lie flat for 30 minutes
• Patient affiliated to a social security scheme

Exclusion Criteria:

• Patient diagnosed with a diagnosis of MGUS (Monoclonal Gammapathy of Undetermined Significance = monoclonal gammopathy of undetermined significance), indolent myeloma ("smoldering myeloma"), non-secreting myeloma or recurrent myeloma,
• Patient already under treatment for myeloma.
• Patient not eligible for intensive treatment followed by a HSC autograft.
• Patient with concomitant neoplasia
• Patient with a history of hematological or solid neoplasia, except if it is a basal cell carcinoma of the skin or an adenocarcinoma in situ of the uterine cervix.
• Patient with a history of sarcoidosis
• Uncontrolled diabetes.
• Patient treated with long-term corticosteroids
• Patient being treated with hematopoietic growth factors
• Patient in sepsis.
• Claustrophobic patient.
• Refusal of patient consent.
• Pregnant or lactating woman.
• Women of childbearing potential without effective contraception.
• Person deprived of liberty or under guardianship
• Impossibility to submit to the medical follow-up of the trial for geographic, social or psychological reasons.
• History of allergic reaction attributed to 18F-fluorodeoxyglucose or to 18F-fluorocholine.